Frameshift peptide vaccine for the prevention lynch syndrome-associated gastrointestinal cancer HHSN2612015000391 torfp: 2018-E12 POP: 9/17/2018 to 3/16/2021
Ended Awarded Last action
- Contract number
- 75N91018F00005
- Awardee
-
Weill Medical College Of Cornell University UEI YNT8TCJH8FQ8 Part of Cornell University
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $891,984
Award facts
- Opportunity
-
- N01CN5500347 Solicitation number
- Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Sep 25, 2015
- Preclinical PREVENT Cancer Program for Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Jan 5, 2015
- Contract value 100% obligated
- $891,983.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- New York, NY 10065, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$2,848 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $894,832 |
About this award
Weill Medical College of Cornell University was awarded a delivery order against the PREVENT Cancer Program (PREVENT) multiple award IDIQ by the National Cancer Institute, an agency of the Department of Health and Human Services. The delivery order has a potential value of $891,983.59 to support the development of a Frameshift Peptide Vaccine for the Prevention of Lynch Syndrome-Associated Gastrointestinal Cancer. No set-aside designation was used for this award. The period of performance is from September 17, 2018 through March 16, 2021. The PREVENT IDIQ aims to provide preclinical efficacy testing, biomarker evaluation, analytical assay development, and other services to aid in developing new cancer prevention regimens for clinical trials. Weill Medical College of Cornell University will utilize this delivery order to further the National Cancer Institute's mission of reducing the burden of cancer through cancer prevention research.
Quick answers
Who was awarded contract 75N91018F00005?
75N91018F00005 was awarded to Weill Medical College Of Cornell University by National Cancer Institute (National Institutes of Health) on September 13, 2018.
How much is contract 75N91018F00005 worth?
The government has obligated $891,984 on 75N91018F00005.
Is contract 75N91018F00005 an order under another contract?
Yes. 75N91018F00005 is a delivery order under HHSN261201500039I, an indefinite delivery contract, on PREVENT Cancer Program (PREVENT).
Was contract 75N91018F00005 competed?
The extent of competition for 75N91018F00005 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award